Literature DB >> 6157011

Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis.

O R Hommers, K J Lamers, P Reekers.   

Abstract

39 patients with chronic-progressive multiple sclerosis were treated with a short course of intensive immunosuppression in high doses of cyclophosphamide and prednisone. The follow-up period varied between 1 and 5 years with a mean of 21/2 years. Progression of the disease ceased in 27 patients for varying periods, with a mean of two years. In 13 patients the progression ceased during the whole follow-up period. The treatment gave the most favourable results in patients who were DRw2 positive in histocompatibility testing, whose disease started at an early age (around 28 years), whose disease duration before treatment was short (6 years), whose progression was fast and whose disability before treatment was low. If CSF levels of IgG3 months after the treatment remain low, this is a sign of good prognosis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6157011     DOI: 10.1007/BF00313182

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  15 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  [Studies with gamma globulin labeled with radioiodine on the origin of protein bodies in the cerebrospinal fluid].

Authors:  E FRICK; L SCHEID-SEYDEL
Journal:  Klin Wochenschr       Date:  1958-09-15

3.  Some aspects of the natural history of disseminated sclerosis.

Authors:  D McALPINE; N COMPSTON
Journal:  Q J Med       Date:  1952-04

4.  Clinical data and the identification of special forms of multiple sclerosis in 1271 cases studied with a standardized documentation system.

Authors:  S Poser; J Wikström; H J Bauer
Journal:  J Neurol Sci       Date:  1979-02       Impact factor: 3.181

5.  Letter: Histocompatibility determinants in multiple sclerosis.

Authors:  L Degos; J Dausset
Journal:  Lancet       Date:  1974-02-23       Impact factor: 79.321

6.  Histocompatibility determinants in multiple sclerosis, with special reference to clinical course.

Authors:  C Jersild; T Fog; G S Hansen; M Thomsen; A Svejgaard; B Dupont
Journal:  Lancet       Date:  1973-12-01       Impact factor: 79.321

Review 7.  On cerebrospinal fluid immunoglobulin-G (IgG) quotients in multiple sclerosis and other diseases. A review and a new formula to estimate the amount of IgG synthesized per day by the central nervous system.

Authors:  W Tourtellotte
Journal:  J Neurol Sci       Date:  1970-03       Impact factor: 3.181

8.  Lymphocyte subpopulations in multiple scerlosis: comparison with neuroelectric blocking activity.

Authors:  C L Schauf; V Schauf; F A Davis; A J Strelkauskas; M R Mizen
Journal:  Neurology       Date:  1977-09       Impact factor: 9.910

9.  Measurement of IgG and albumin content of cerebrospinal fluid, and its interpretation.

Authors:  K Ganrot; C B Laurell
Journal:  Clin Chem       Date:  1974-05       Impact factor: 8.327

10.  HLA-typing and lymphocyte population studies in patients with multiple sclerosis.

Authors:  P Reekers; O R Hommes; J Creemers-Molenaar; J Wijnings; V A Kunst; J J Van Rood
Journal:  J Neurol Sci       Date:  1977-08       Impact factor: 3.181

View more
  15 in total

1.  Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study.

Authors:  L La Mantia; M Eoli; A Salmaggi; V Torri; C Milanese
Journal:  Ital J Neurol Sci       Date:  1998-02

2.  24-month follow-up of multiple sclerosis patients treated with cyclophosphamide.

Authors:  E Millefiorini; M Di Giovanni; S Bernardi; M G Grasso; A Di Giampietro; D Gambi
Journal:  Ital J Neurol Sci       Date:  1990-12

Review 3.  Cyclophosphamide for multiple sclerosis.

Authors:  L La Mantia; C Milanese; N Mascoli; R D'Amico; B Weinstock-Guttman
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

4.  The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.

Authors:  K J Lamers; B M Uitdehaag; O R Hommes; W Doesburg; R A Wevers; W J von Geel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-10       Impact factor: 10.154

5.  The need for a new strategy for the treatment of multiple sclerosis.

Authors:  A N Davison
Journal:  J Neurol       Date:  1988-07       Impact factor: 4.849

Review 6.  Role of immunosuppressive therapy for the treatment of multiple sclerosis.

Authors:  James M Stankiewicz; Hadar Kolb; Arnon Karni; Howard L Weiner
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

7.  Cyclophosphamide in relapsing remitting multiple sclerosis.

Authors:  F D'Andrea; C D'Aurizio; C Marini; M Prencipe
Journal:  Ital J Neurol Sci       Date:  1990-06

8.  Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.

Authors:  W H Likosky; B Fireman; R Elmore; G Eno; K Gale; G B Goode; K Ikeda; J Laster; C Mosher; J Rozance
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-12       Impact factor: 10.154

9.  Effective treatment of chronically progressive multiple sclerosis with low-dose cyclophosphamide with minor side-effects.

Authors:  E Mauch; H H Kornhuber; U Pfrommer; A Hähnel; H Laufen; H Krapf
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

10.  Immunological treatment of multiple sclerosis.

Authors:  R A Hughes
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.